The first and only FDA-approved treatment for nonsegmental vitiligo is a topical cream that you can apply yourself. Use OPZELURA twice daily on depigmented areas of skin on up to 10% of body surface area, keeping in mind the instructions below on how and when to apply it.
Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Please talk with your healthcare provider about how best to use OPZELURA in relation to any personal hygiene routines or cosmetic products.
Apply a thin layer of OPZELURA twice daily on your body's affected areas—up to 10% of your body based on the direction from your healthcare provider. That's about the size of ten handprints. If you're still unsure, ask your healthcare provider for guidance on how much to use and where you should apply OPZELURA. Do not use more than one 60 gram tube each week.
*OPZELURA is for use on the skin only. Do not use in the eyes, mouth, or vagina.
You may be an important piece of their support system. By getting to know the specifics of their treatment plan, you can help them stay consistent with their new schedule.
The color in your skin is made by pigment-producing cells (melanocytes) that mainly come from the hair follicles. So, if your skin begins to repigment, the first freckles of skin color may show up around the hair follicles. New pigment may also appear at the edges of your depigmented patches.
Wondering what's possible with OPZELURA? Reimagine what repigmentation can look like. The following photos include computer-generated images of study results. They have been created based on the data shown in two clinical trials for OPZELURA. OPZELURA was studied in two clinical trials for 6 months in participants aged 12 and older with nonsegmental vitiligo on up to 10% of their total body surface area (BSA). Phototherapy was not permitted during the trial. These photos represent pigmentation before treatment with OPZELURA, after 3 months of treatment, and at 6 months of treatment. Repigmentation may continue beyond 6 months.
Areas where the hair follicles are sparse, absent or have turned white may not repigment.
Real person with vitiligo; not an OPZELURA patient. Includes computer-generated images of results.
Individual results may vary. Results not typical.
OPZELURA results were studied in some clinical trial patients through 2 years.
We're here to help as you talk with your
healthcare provider about whether
OPZELURA may be right for you.
Receive timely information, updates,
and helpful tips about OPZELURA sent
directly to you.
OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with nonsegmental vitiligo.
OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.
OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.
Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.
Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.
Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.
Before starting OPZELURA, tell your healthcare provider if you:
After starting OPZELURA:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.
These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.
Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.
